T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE3
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
- Status
- COMPLETED
- Phase
- PHASE2
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
- Status
- COMPLETED
- Phase
- PHASE2
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
- Status
- COMPLETED
- Phase
- PHASE1
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
- Status
- UNKNOWN
- Phase
- PHASE2
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1